16 results
8-K
SQZB
SQZ Biotechnologies Co
6 Dec 22
Designation Represents Potential to Bring Important New Therapy to Patients Earlier
4:23pm
at the European Society for Medical Oncology Immuno-Oncology ("ESMO-IO") Congress. Data also demonstrated that its APC and eAPC therapeutic candidates were well
8-K
EX-99.1
SQZB
SQZ Biotechnologies Co
6 Dec 22
Designation Represents Potential to Bring Important New Therapy to Patients Earlier
4:23pm
for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress
Designation … at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress. Data also demonstrated that its APC and eAPC therapeutic candidates were well
8-K
EX-99.1
SQZB
SQZ Biotechnologies Co
30 Nov 22
Cost Associated with Exit or Disposal Activities
4:32pm
enhanced Antigen Presenting Cells therapy and has initiated switching select APC sites to the eAPC clinical trial. At European Society of Medical
8-K
EX-99.1
qqjc6m1lhnrurkv15qt1
24 Jan 22
SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors
7:01am
8-K
EX-99.1
virjdjrqnfklzch
9 Dec 21
Other Events
7:30am
8-K
snvyqi3
9 Dec 21
Other Events
7:30am
8-K
v4w mn9f1
2 Dec 21
Other Events
6:28am
8-K
EX-99.1
bdndearsb9ff37jpgsi
2 Dec 21
Other Events
6:28am
8-K
EX-99.1
ykshsimi aj8l5b
26 Oct 21
SQZ Biotechnologies Announces Independent DSMB Recommendation to Advance Lead Cell Therapy Candidate into Combination
6:54am
8-K
EX-99.1
guaynue
13 Sep 21
SQZ Biotechnologies Announces First Autoimmune Disease Indication
6:53am
8-K
EX-99.1
8170ynnh g8dyf6
4 Jun 21
Regulation FD Disclosure
8:09am
- Prev
- 1
- Next